Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis

BACKGROUND: The first- and second-trimester screening for trisomy 21 (T21) are reimbursed for all pregnant women in Belgium. Using a cut-off risk of 1:300 for T21, about 5% of all pregnant women are referred for definitive prenatal diagnosis using an invasive test, at a sensitivity of (only) 72.5%....

Descripción completa

Detalles Bibliográficos
Autores principales: Neyt, Mattias, Hulstaert, Frank, Gyselaers, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225226/
https://www.ncbi.nlm.nih.gov/pubmed/25380810
http://dx.doi.org/10.1136/bmjopen-2014-005922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225226/
https://www.ncbi.nlm.nih.gov/pubmed/25380810
http://dx.doi.org/10.1136/bmjopen-2014-005922

Ejemplares similares